EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression

Tsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, Li-Chun Lu, Po-Ting Lin, Yung-Yeh Su, Wei Teng, Shiue-Wei Lai, Ren-Hua Yeh, Tsui-Mai Kao, Pei-Chang Lee, Chi-Jung Wu und 8 weitere

Liver Cancer · 01.02.2024 · 13 (5) · 509-521

DOI: 10.1159/000536549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 01.02.2024. Verfasst von Tsung-Hao Liu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized.

Methods

Patients with advanced HCC who received immune checkpoint inhibitor (ICI)-based immunotherapy and achieved durable responses were retrospectively included. A durable response was defined as partial response (PR) or stable disease (SD) per RECIST 1.1 for more than 8 months after initiation of immunotherapy. Oligoprogression and polyprogression were defined as progression at ≤3 and >3 lesions, respectively.

Results

A total of 91 durable responders (63 PR and 28 SD) were identified. The majority had chronic viral hepatitis (n = 69, 75.8%). Forty-seven (51.6%) and 44 (48.4%) patients received the index immunotherapy as first-line and second- or beyond-line therapy, respectively. Fifty-four (59.3%) patients subsequently developed progression, with a predominant pattern of oligoprogression (66.7%). The median overall survival (OS) was 46.2 months (95% CI: 34.1–58.3). For patients with subsequent progression, employment of locoregional therapy (LRT) for progression was associated with prolonged OS (univariate analysis: hazard ratio [HR] 0.397, p = 0.009; multivariate analysis: HR 0.363, p = 0.050). Patients with oligoprogression who received LRT showed longer median OS than those who did not (48.4 vs. 20.5 months, p < 0.001). In contrast, the median OS of patients with polyprogression who received LRT was not different from those without LRT (27.7 vs. 25.5 months, p = 0.794).

Conclusion

Approximately 60% of the post-immunotherapy durable responders of HCC subsequently develop progression. Proactive LRT may further rescue patients who develop subsequent oligoprogression. Prospective studies are mandatory to clarify the proper management of durable responders with subsequent progression.

Schlagwörter

Stichwörter der Autor:innen

Durable responseHepatocellular carcinomaImmunotherapyLocoregional therapyOligoprogression

Autor:innen und Institutionen

  • Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.
  • Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan.
  • Division of Medical Oncology, Center of Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan.
  • Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung City, Taiwan.
  • Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Zitieren

APA

Liu, T. H., Chen, S. C., Rau, K. M., Lu, L. C., Lin, P. T., Su, Y. Y., Teng, W., Lai, S. W., Yeh, R. H., Kao, T. M., Lee, P. C., Wu, C. J., Chen, C. H., Hsu, C. H., Lin, S. M., Huang, Y. H., Chen, L. T., Cheng, A. L., Shen, Y. C., & Taiwan Liver Cancer Association Research Group (TRG) (2024). Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression. Liver Cancer, 13(5), 509-521. https://doi.org/10.1159/000536549

Vancouver

Liu TH, Chen SC, Rau KM, Lu LC, Lin PT, Su YY, et al. Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression. Liver Cancer. 2024;13(5):509-521. doi:10.1159/000536549

BibTeX
@article{Liu2024,
  author = {Liu, Tsung-Hao and Chen, San-Chi and Rau, Kun-Ming and Lu, Li-Chun and Lin, Po-Ting and Su, Yung-Yeh and Teng, Wei and Lai, Shiue-Wei and Yeh, Ren-Hua and Kao, Tsui-Mai and Lee, Pei-Chang and Wu, Chi-Jung and Chen, Chien-Hung and Hsu, Chih-Hung and Lin, Shi-Ming and Huang, Yi-Hsiang and Chen, Li-Tzong and Cheng, Ann-Lii and Shen, Ying-Chun and Taiwan Liver Cancer Association Research Group (TRG), Taiwan Liver Cancer Association Research Group (TRG)},
  title = {Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression},
  journal = {Liver Cancer},
  year = {2024},
  volume = {13},
  number = {5},
  pages = {509--521},
  doi = {10.1159/000536549}
}
Kostenlos starten →